Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | XDH | P47989 | 6/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | THRB | P10828 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.33 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.33 |
| ▸ | PNP | P00491 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24239185 | 0.81 | PNP (0.46) | XDHALDH1A1THRBL3MBTL1PNP | |
| SCHEMBL23228226 | 0.76 | BRD4 (0.39) | ALDH1A1HSP90AA1HSP90AB1PNP | |
| SCHEMBL23228197 | 0.76 | SMN1; SMN2 (0.44) | XDHALDH1A1L3MBTL1 | |
| SCHEMBL24236963 | 0.69 | HPGD (0.46) | XDHALDH1A1THRBL3MBTL1HSP90AA1 | |
| SCHEMBL22326779 | 0.68 | ALDH1A1 (0.34) | XDHALDH1A1THRBL3MBTL1 | |
| Hydrochloric Acid SCHEMBL7296125 | 0.64 | PNP (0.40) | XDHALDH1A1THRBL3MBTL1PNP | |
| SCHEMBL24499589 | 0.62 | XDH (0.40) | XDHALDH1A1THRBL3MBTL1PNP | |
| SCHEMBL18519852 | 0.62 | PNP (0.45) | XDHALDH1A1PNP | |
| SCHEMBL23679550 | 0.62 | PNP (0.45) | XDHPNP | |
| SCHEMBL22381533 | 0.60 | PNP (0.42) | XDHALDH1A1PNP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11666594-B2 | Antibody-drug conjugates comprising a cyclic dinucleotide | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-06-06 | — | — | US | disclosed |
| US-20210106607-A1 | ANTIBODY-DRUG CONJUGATES COMPRISING A CYCLIC DINUCLEOTIDE | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-04-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210106607-A1 | ANTIBODY-DRUG CONJUGATES COMPRISING A CYCLIC DINUCLEOTIDE | STING1, TLR9, CGAS | XDH 1435/4885ALDH1A1 3598/4885THRB 3886/4885 |
| US-11666594-B2 | Antibody-drug conjugates comprising a cyclic dinucleotide | STING1, TLR9, CGAS | XDH 1435/4885ALDH1A1 3598/4885THRB 3886/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.